142 related articles for article (PubMed ID: 24043748)
1. Aurora kinase inhibition as an anticancer strategy.
Hilton JF; Shapiro GI
J Clin Oncol; 2014 Jan; 32(1):57-9. PubMed ID: 24043748
[No Abstract] [Full Text] [Related]
2. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
[TBL] [Abstract][Full Text] [Related]
3. First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator’s Choice (LUMIERE trial; NCT01482962).
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):12-3. PubMed ID: 27466629
[No Abstract] [Full Text] [Related]
4. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D; Pettengell R
Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
Zhou X; Lockhart AC; Fu S; Nemunaitis J; Sarantopoulos J; Muehler A; Rangachari L; Bargfrede M; Venkatakrishnan K
J Clin Pharmacol; 2019 Sep; 59(9):1204-1215. PubMed ID: 30985952
[TBL] [Abstract][Full Text] [Related]
6. Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
Zullo KM; Guo Y; Cooke L; Jirau-Serrano X; Mangone M; Scotto L; Amengual JE; Mao Y; Nandakumar R; Cremers S; Duong J; Mahadevan D; O'Connor OA
Clin Cancer Res; 2015 Sep; 21(18):4097-109. PubMed ID: 25878331
[TBL] [Abstract][Full Text] [Related]
7. Learnings from phosphatidylinositol 3-kinase inhibitors in lymphoma-Moving to a model where less can be more.
Martynchyk A; Hawkes EA
Br J Haematol; 2024 May; 204(5):1582-1584. PubMed ID: 38581289
[TBL] [Abstract][Full Text] [Related]
8. Introduction of novel agents in the treatment of primary CNS lymphoma.
Grommes C; Nayak L; Tun HW; Batchelor TT
Neuro Oncol; 2019 Feb; 21(3):306-313. PubMed ID: 30423172
[TBL] [Abstract][Full Text] [Related]
9. 57th American Society of Hematology Annual Meeting.
Smith LL
Lancet Oncol; 2016 Feb; 17(2):142. PubMed ID: 26687594
[No Abstract] [Full Text] [Related]
10. A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
Cohen JB; Maddocks KJ; Huang Y; Christian BA; Jaglowski SM; Flowers CR; Blum KA
Leuk Lymphoma; 2017 Sep; 58(9):1-2. PubMed ID: 28278718
[No Abstract] [Full Text] [Related]
11. Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib.
Necchi A; Pintarelli G; Raggi D; Giannatempo P; Colombo F
Invest New Drugs; 2017 Aug; 35(4):524-528. PubMed ID: 28155045
[TBL] [Abstract][Full Text] [Related]
12. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
13. Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR.
Zhang Q; Shen Q; Gao L; Tong L; Li J; Chen Y; Lu W
Eur J Med Chem; 2018 Oct; 158():428-441. PubMed ID: 30241010
[TBL] [Abstract][Full Text] [Related]
14. The role of alisertib in treatment of peripheral T-cell lymphomas.
Gallop-Evans E
Future Oncol; 2015 Sep; 11(18):2515-24. PubMed ID: 26344156
[TBL] [Abstract][Full Text] [Related]
15. Antineoplastic and immunosuppressive drugs. II. Therapeutic uses.
Cridland MD
Drugs; 1972; 3(5):331-51. PubMed ID: 4347084
[No Abstract] [Full Text] [Related]
16. Factors predictive for response of follicular and mantle-cell lymphoma to rituximab.
Pfreundschuh M
Nat Clin Pract Oncol; 2006 Apr; 3(4):184-5. PubMed ID: 16596141
[No Abstract] [Full Text] [Related]
17. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Chan TS; Khong PL; Kwong YL
Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
[No Abstract] [Full Text] [Related]
18. Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data.
Tayyar Y; Jubair L; Fallaha S; McMillan NAJ
Crit Rev Oncol Hematol; 2017 Nov; 119():59-65. PubMed ID: 29065986
[TBL] [Abstract][Full Text] [Related]
19. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
Tuccilli C; Baldini E; Prinzi N; Morrone S; Sorrenti S; Filippini A; Catania A; Alessandrini S; Rendina R; Coccaro C; D'Armiento M; Ulisse S
Endocrine; 2016 May; 52(2):287-95. PubMed ID: 26215279
[TBL] [Abstract][Full Text] [Related]
20. First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (LUMIERE trial; NCT01482962).
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):12-3. PubMed ID: 27007010
[No Abstract] [Full Text] [Related]
[Next] [New Search]